Germany - Drugs

Description

The present OHV is not subject to public procurement law and has already been published in the Supplement to the Official Journal of the EU with OJEU 2023/S 079-237358 (initial notice). The contracting authority has extended the procurement requirements for this procedure and hereby announces this in accordance with its announcement under Section II.2.4) of the initial announcement and Section A.I.4.1 of the Conditions of Participation (subsequent announcement). The AOK BW intends to conclude non-exclusive discount contracts pursuant to Section 130a (8) SGB V with all suitable pharmaceutical companies for drugs with the active ingredients named in Annex 3 to the Conditions of Participation. The contract term for the active ingredients/active ingredient combinations in accordance with Section II.2.4) of the initial announcement begins on July 1, 2023 at the earliest and lasts a maximum of 24 months. The contract term for the active ingredients/active ingredient combinations in accordance with Section II.2.4) of this follow-up announcement shall commence on August 1, 2023 at the earliest and shall not exceed 23 months.
The procurement requirements of OHV 2023 include all drugs with the active ingredients named in Annex 3 to the conditions of participation (so-called active ingredient list and deadlines). The AOK Baden-Württemberg (AOK) has extended the procurement requirement of the open house procedure already announced by the notice OJ EU 2023/S 079-237358 to the effect that agreements pursuant to Section 130a (8) SGBV are also to be concluded for the drugs with the following combination of active ingredients within the framework of this open house procedure: Beclometasone dipropionate + formoterol hemifumarate-1-water (ref. no. 10 of Annex 3 to the Conditions of Participation, as of May 31, 2023).Annex 3 to the Conditions of Participation has been supplemented accordingly and is available to interested companies after free registration - together with the other procedural documents - on the award platform (see section I.3) of this announcement). The AOK reserves the right to expand the procurement requirements of this open house procedure to include additional active ingredients in the course of the further procedure. Further information on a possible expansion of the procurement requirement is contained in the conditions of participation (section A.I.4.1).Contracts for drugs with the above-mentioned combination of active ingredients will be concluded with effect from August 1, 2023 at the earliest. All discount contracts concluded within the scope of this open house procedure will end uniformly on June 30, 2025. For the earliest possible start of discount contracts with the above-mentioned combination of active ingredients on August 1, 2023, interested companies must submit a complete bid in accordance with the participation documents no later than June 20, 2023, exclusively in electronic form via the communication area of the award platform. Contracts for the above-mentioned combination of active ingredients will be concluded no earlier than July 3, 2023 (waiting and standstill period). The conclusion of a discount contract for medicinal products with the above-mentioned combination of active ingredients at a later date than 1.8.2023 is possible on the first day of each month. The offers must be submitted in full no later than 6 weeks before the intended start of the contract. The respective deadlines for the submission of bids in relation to the intended start of the contract by the interested pharmaceutical company can be found in Annex 3 to the Conditions of Participation. For all contracts to be concluded within the scope of this open house procedure, the last possible contract start date is 1.6.2025. Offers for this contract start date must be received by 17.4.2025 at the latest. The AOK shall specify the content of the discount contract in a binding manner for all potential contract partners. Negotiations on contract contents will not be conducted. The AOK does not assure exclusivity to the contract partners. In the event of the conclusion of a contract, the pharmaceutical entrepreneur shall grant the AOK a discount on the contractual medicinal products which are dispensed at the expense of the AOK in accordance with the more detailed provisions of the Conditions of Participation and the Discount Agreement (for the specified discount amount and discount calculation, reference is made in particular to Sections A.I.4.3, A.I.5 and A.I.7 of the Conditions of Participation as well as Section 2 Paragraph (2) and Section 4 Paragraph (3) of the Discount Agreement.

Opportunity closing date

17 April 2025

Value of contract

to be confirmed